51
|
Mund JA, Ingram DA, Yoder MC, Case J. Endothelial progenitor cells and cardiovascular cell-based therapies. Cytotherapy 2009; 11:103-13. [PMID: 19241233 DOI: 10.1080/14653240802714827] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Since their initial discovery more than a decade ago, bone marrow (BM)-derived circulating endothelial progenitor cells (EPC) have been reported to play a role in postnatal vasculogenesis through vessel regeneration and remodeling. These cells have been reported to mobilize into the blood stream in response to vascular injury, and differentiate into cells expressing a host of endothelial cell (EC) markers in vitro. Because of demonstrable regenerative capacity in animal models of human disease, EPC are thought to represent a novel treatment option for problematic cardiovascular conditions such as myocardial infarction (MI) and peripheral vascular disease (PVD). Various studies have been performed to test the clinical efficacy of EPC in patients with cardiovascular disease (CVD), including the mobilization of EPC with pharmacologic agents in patients with heart disease, and harvesting of cells from the circulation and BM for autologous reinfusion in affected patients. The outcomes of these trials have been mixed and not as robust as predicted from the animal models, partly because of the variation in the definition of human EPC and the resulting heterogeneity in cell populations used in the treatments. This review will decipher a number of published studies that have been conducted to examine cell therapies for treatment of CVD, will attempt to explain why efficacy of treatment with putative EPC has been inconsistent, and predict which aspects of these trials may need to be redesigned for future successful treatment of CVD.
Collapse
Affiliation(s)
- Julie A Mund
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis, 46202, USA
| | | | | | | |
Collapse
|
52
|
Laurenti E, Wilson A, Trumpp A. Myc's other life: stem cells and beyond. Curr Opin Cell Biol 2009; 21:844-54. [PMID: 19836223 DOI: 10.1016/j.ceb.2009.09.006] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2009] [Revised: 09/15/2009] [Accepted: 09/18/2009] [Indexed: 12/17/2022]
Abstract
Over the last three decades genetic and biochemical studies have revealed the pleiotropic effects of the Myc oncoprotein. While cell line studies have defined the intracellular processes regulated by Myc such as proliferation, differentiation, and metabolic growth, in vivo studies have confirmed these functions, and revealed roles in acquisition and maintenance of stem cell properties. These roles may be partially mediated by Myc's capacity to modify the chromatin landscape on a global scale. Myc also regulates numerous protein-coding transcripts, and many noncoding RNAs (rRNAs, tRNAs, and miRNAs). As Myc activity directly correlates with protein expression, further complexity is provided by post-translational modifications that regulate Myc in normal stem cells or deregulate it in malignant stem cells.
Collapse
Affiliation(s)
- Elisa Laurenti
- Ludwig Institute for Cancer Research Ltd, Lausanne Branch, University of Lausanne, Switzerland
| | | | | |
Collapse
|
53
|
Stoelzle T, Schwarb P, Trumpp A, Hynes NE. c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland. BMC Biol 2009; 7:63. [PMID: 19785743 PMCID: PMC2761394 DOI: 10.1186/1741-7007-7-63] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2009] [Accepted: 09/28/2009] [Indexed: 11/11/2022] Open
Abstract
Background The oncoprotein c-Myc has been intensely studied in breast cancer and mouse mammary tumor models, but relatively little is known about the normal physiological role of c-Myc in the mammary gland. Here we investigated functions of c-Myc during mouse mammary gland development using a conditional knockout approach. Results Generation of c-mycfl/fl mice carrying the mammary gland-specific WAPiCre transgene resulted in c-Myc loss in alveolar epithelial cells starting in mid-pregnancy. Three major phenotypes were observed in glands of mutant mice. First, c-Myc-deficient alveolar cells had a slower proliferative response at the start of pregnancy, causing a delay but not a block of alveolar development. Second, while milk composition was comparable between wild type and mutant animals, milk production was reduced in mutant glands, leading to slower pup weight-gain. Electron microscopy and polysome fractionation revealed a general decrease in translational efficiency. Furthermore, analysis of mRNA distribution along the polysome gradient demonstrated that this effect was specific for mRNAs whose protein products are involved in milk synthesis. Moreover, quantitative reverse transcription-polymerase chain reaction analysis revealed decreased levels of ribosomal RNAs and ribosomal protein-encoding mRNAs in mutant glands. Third, using the mammary transplantation technique to functionally identify alveolar progenitor cells, we observed that the mutant epithelium has a reduced ability to repopulate the gland when transplanted into NOD/SCID recipients. Conclusion We have demonstrated that c-Myc plays multiple roles in the mouse mammary gland during pregnancy and lactation. c-Myc loss delayed, but did not block proliferation and differentiation in pregnancy. During lactation, lower levels of ribosomal RNAs and proteins were present and translation was generally decreased in mutant glands. Finally, the transplantation studies suggest a role for c-Myc in progenitor cell proliferation and/or survival. See related minireview by Evan et al:
Collapse
Affiliation(s)
- Tina Stoelzle
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
| | | | | | | |
Collapse
|
55
|
Kokai E, Voss F, Fleischer F, Kempe S, Marinkovic D, Wolburg H, Leithäuser F, Schmidt V, Deutsch U, Wirth T. Myc Regulates Embryonic Vascular Permeability and Remodeling. Circ Res 2009; 104:1151-9. [DOI: 10.1161/circresaha.108.191460] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Previous work has shown that c-Myc is required for adequate vasculogenesis and angiogenesis. To further investigate the contribution of Myc to these processes, we conditionally expressed c-Myc in embryonic endothelial cells using a tetracycline-regulated system. Endothelial Myc overexpression resulted in severe defects in the embryonic vascular system. Myc-expressing embryos undergo widespread edema formation and multiple hemorrhagic lesions. They die between embryonic days 14.5 and 17.5. The changes in vascular permeability are not caused by deficiencies in vascular basement membrane composition or pericyte coverage. However, the overall turnover of endothelial cells is elevated as is revealed by increased levels of both proliferation and apoptosis. Whole-mount immunohistochemical analysis revealed alterations in the architecture of capillary networks. The dermal vasculature of Myc-expressing embryos is characterized by a reduction in vessel branching, which occurs despite upregulation of the proangiogenic factors vascular endothelial growth factor-A and angiopoietin-2. Thus, the net outcome of an excess of vascular endothelial growth factor-A and angiopoietin-2 in the face of an elevated cellular turnover appears to be a defect in vascular integrity.
Collapse
Affiliation(s)
- Enikö Kokai
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Florian Voss
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Frank Fleischer
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Sybille Kempe
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Dragan Marinkovic
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Hartwig Wolburg
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Frank Leithäuser
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Volker Schmidt
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Urban Deutsch
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| | - Thomas Wirth
- From the Institute of Physiological Chemistry (E.K., S.K., D.M., T.W.), Department of Pathology (F.L.), and Institute of Stochastics (F.V., F.F., V.S.), Ulm University, Germany; Institute of Pathology (H.W.), University of Tübingen Germany; and Theodor Kocher Institute (U.D.), University Bern, Switzerland
| |
Collapse
|
56
|
Abstract
It has been found that c-Myc protein plays a critical role in controlling self-renewal versus differentiation in hematopoietic stem cells. We report that c-Myc also controls the fate of megakaryocyte-erythrocyte progenitors through regulating the differentiation of erythroid and megakaryocytic progenitors. In addition to the significant reduction of granulocytes/macrophages and B and T lymphocytes because of the reduction of their corresponding progenitors, we found significantly increased numbers of megakaryocytic progenitors and mature megakaryocytes in bone marrow and spleens of c-Myc-knockout (c-Myc(-/-)) mice. Differentiation of erythrocytes was blocked at the erythroid progenitor stage. This increased megakaryocytopoiesis is a cell-intrinsic defect of c-Myc-mutant hematopoietic stem cells, as shown by transplantation studies. Furthermore, we found that c-Myc is required for polyploidy formation but not for cytoplasmic maturation of megakaryocytes. Megakaryocytes from c-Myc(-/-) mice are significantly smaller in size and lower in ploidy than those of control mice; however, because of the dramatic increase in megakaryocyte number, although fewer platelets are produced by each megakaryocyte, a greater than 3-fold increase in platelet number was consistently observed in c-Myc(-/-) mice. Thus, c-Myc(-/-) mice develop a syndrome of severe thrombocytosis-anemia-leukopenia because of significant increases in megakaryocytopoiesis and concomitant blockage of erythrocyte differentiation and reductions in myelolymphopoiesis.
Collapse
|
57
|
Kim YH, Hu H, Guevara-Gallardo S, Lam MTY, Fong SY, Wang RA. Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development 2009; 135:3755-64. [PMID: 18952909 DOI: 10.1242/dev.022475] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A mutual coordination of size between developing arteries and veins is essential for establishing proper connections between these vessels and, ultimately, a functional vasculature; however, the cellular and molecular regulation of this parity is not understood. Here, we demonstrate that the size of the developing dorsal aorta and cardinal vein is reciprocally balanced. Mouse embryos carrying gain-of-function Notch alleles show enlarged aortae and underdeveloped cardinal veins, whereas those with loss-of-function mutations show small aortae and large cardinal veins. Notch does not affect the overall number of endothelial cells but balances the proportion of arterial to venous endothelial cells, thereby modulating the relative sizes of both vessel types. Loss of ephrin B2 or its receptor EphB4 also leads to enlarged aortae and underdeveloped cardinal veins; however, endothelial cells with venous identity are mislocalized in the aorta, suggesting that ephrin B2/EphB4 signaling functions distinctly from Notch by sorting arterial and venous endothelial cells into their respective vessels. Our findings provide mechanistic insight into the processes underlying artery and vein size equilibration during angiogenesis.
Collapse
Affiliation(s)
- Yung Hae Kim
- Department of Surgery, University of California, San Francisco, CA 94143, USA
| | | | | | | | | | | |
Collapse
|
59
|
Dubois NC, Adolphe C, Ehninger A, Wang RA, Robertson EJ, Trumpp A. Placental rescue reveals a sole requirement for c-Myc in embryonic erythroblast survival and hematopoietic stem cell function. Development 2008; 135:2455-65. [PMID: 18550708 DOI: 10.1242/dev.022707] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The c-Myc protein has been implicated in playing a pivotal role in regulating the expression of a large number of genes involved in many aspects of cellular function. Consistent with this view, embryos lacking the c-myc gene exhibit severe developmental defects and die before midgestation. Here, we show that Sox2Cre-mediated deletion of the conditional c-myc(flox) allele specifically in the epiblast (hence trophoectoderm and primitive endoderm structures are wild type) rescues the majority of developmental abnormalities previously characterized in c-myc knockout embryos, indicating that they are secondary defects and arise as a result of placental insufficiency. Epiblast-restricted c-Myc-null embryos appear morphologically normal and do not exhibit any obvious proliferation defects. Nonetheless, these embryos are severely anemic and die before E12. c-Myc-deficient embryos exhibit fetal liver hypoplasia, apoptosis of erythrocyte precursors and functionally defective definitive hematopoietic stem/progenitor cells. Specific deletion of c-myc(flox) in hemogenic or hepatocytic lineages validate the hematopoietic-specific requirement of c-Myc in the embryo proper and provide in vivo evidence to support a synergism between hematopoietic and liver development. Our results reveal for the first time that physiological levels of c-Myc are essential for cell survival and demonstrate that, in contrast to most other embryonic lineages, erythroblasts and hematopoietic stem/progenitor cells are particularly dependent on c-Myc function.
Collapse
Affiliation(s)
- Nicole C Dubois
- Ecole Polytechnique Fédérale de Lausanne, Swiss Institute for Experimental Cancer Research, School of Life Science, 1066 Epalinges, Switzerland
| | | | | | | | | | | |
Collapse
|